Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Receivables - Other (2016 - 2021)

Historic Receivables - Other for Myriad Genetics (MYGN) over the last 12 years, with Q1 2021 value amounting to $2.4 million.

  • Myriad Genetics' Receivables - Other fell 400.0% to $2.4 million in Q1 2021 from the same period last year, while for Mar 2021 it was $2.4 million, marking a year-over-year decrease of 400.0%. This contributed to the annual value of $2.0 million for FY2020, which is N/A changed from last year.
  • Per Myriad Genetics' latest filing, its Receivables - Other stood at $2.4 million for Q1 2021, which was down 400.0% from $2.0 million recorded in Q4 2020.
  • In the past 5 years, Myriad Genetics' Receivables - Other ranged from a high of $6.9 million in Q3 2017 and a low of $2.0 million during Q3 2020
  • Over the past 5 years, Myriad Genetics' median Receivables - Other value was $4.3 million (recorded in 2018), while the average stood at $4.1 million.
  • Its Receivables - Other has fluctuated over the past 5 years, first skyrocketed by 7272.73% in 2017, then plummeted by 5833.33% in 2020.
  • Quarter analysis of 5 years shows Myriad Genetics' Receivables - Other stood at $6.0 million in 2017, then decreased by 1.67% to $5.9 million in 2018, then crashed by 40.68% to $3.5 million in 2019, then tumbled by 42.86% to $2.0 million in 2020, then grew by 20.0% to $2.4 million in 2021.
  • Its Receivables - Other was $2.4 million in Q1 2021, compared to $2.0 million in Q4 2020 and $2.0 million in Q3 2020.